↓ Skip to main content

Oncotarget

Article Metrics

What is this page? Embed badge

Germline mutations in pancreatic cancer and potential new therapeutic options

Overview of attention for article published in Oncotarget, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

twitter
29 tweeters

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
92 Mendeley
Summary Twitter Dimensions citations
Title
Germline mutations in pancreatic cancer and potential new therapeutic options
Published in
Oncotarget, April 2017
DOI 10.18632/oncotarget.17291
Pubmed ID
28488580
Authors

Rille Pihlak, Juan W. Valle, Mairéad G. McNamara

Abstract

Due to short-lived treatment responses in unresectable disease, pancreatic ductal adenocarcinoma (PDAC) continues to be one of the deadliest cancers. There is availability of new information about germline and sporadic mutations in the deoxyribonucleic acid (DNA) damage repair pathway in PDAC in recent decades and the expectation is that novel targeted therapies will thus be developed. A variety of germline mutations (BRCA2, BRCA1, PALB2, CDKN2A, ATM, TP53 and mismatch repair genes MLH1, MSH2, MSH6) have been reported in these patients with the highest prevalence being BRCA1/2. Positive results have been reported with the use of targeted therapies, particularly poly (ADP-ribose) polymerase inhibitors in BRCA-mutated ovarian and breast cancers, and their use is currently being investigated in germline-mutated pancreatic cancer. The aim of this review is to provide an outline of germline DNA damage repair mutations in pancreatic cancer and their effect on the incidence, outcomes and responses to different therapeutic options.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 29 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 92 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 24%
Student > Master 13 14%
Student > Bachelor 11 12%
Student > Ph. D. Student 11 12%
Student > Doctoral Student 6 7%
Other 9 10%
Unknown 20 22%
Readers by discipline Count As %
Medicine and Dentistry 28 30%
Biochemistry, Genetics and Molecular Biology 24 26%
Agricultural and Biological Sciences 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Immunology and Microbiology 3 3%
Other 5 5%
Unknown 23 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2018.
All research outputs
#1,744,373
of 23,404,576 outputs
Outputs from Oncotarget
#766
of 14,405 outputs
Outputs of similar age
#35,367
of 311,186 outputs
Outputs of similar age from Oncotarget
#42
of 1,462 outputs
Altmetric has tracked 23,404,576 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,405 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,186 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1,462 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.

This page is hosted by Altmetric on behalf of Oncotarget.